Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA3 | P34903 | 9/20 | 0.76 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.74 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.74 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334038 | 0.87 | GABRA3 (0.72) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL9001310 | 0.87 | GABRA3 (1.00) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL7326033 | 0.86 | GABRA3 (1.00) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL7327203 | 0.85 | GABRA3 (1.00) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL7333576 | 0.85 | GABRA3 (1.00) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL9001271 | 0.84 | GABRA3 (0.61) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL7324558 | 0.83 | GABRA3 (0.68) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL7330881 | 0.83 | GABRA3 (0.68) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL7329402 | 0.83 | GABRA3 (0.83) | GABRA3GABRA2GABRA1GABRA5 | |
| SCHEMBL7330195 | 0.83 | GABRA3 (1.00) | GABRA3GABRA2GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0536360-A4 | TOPICAL TREATMENT OF ACNE | — | 1993-08-04 | — | — | EP | claimed |
| EP-0536295-A1 | CERTAIN AZACYCLOALKYL IMIDAZOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-04-14 | — | — | EP | claimed |
| EP-0536360-A1 | TOPICAL TREATMENT OF ACNE | BLOOM, Leonard (US) | 1993-04-14 | — | — | EP | claimed |
| WO-1992015299-A1 | TOPICAL TREATMENT OF ACNE | BLOOM, LEONARD (US) | 1992-09-17 | — | — | WO | claimed |
| US-5095015-A | G-aminobutyric acid, anticonvulsants, tranquilizers, sleep disorders | NEUROGEN CORPORATION (US) | 1992-03-10 | — | — | US | claimed |
| WO-1992000296-A1 | CERTAIN AZACYCLOALKYL IMIDAZOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-01-09 | — | — | WO | claimed |
| US-5510480-A | FOR SELECTIVE BINDING WITH GAMMA-AMINOBUTYRIC ACID RECEPTORS | NEUROGEN CORPORATION (US) | 1996-04-23 | — | — | US | disclosed |
| US-5328912-A | Psychological disorders, cognition activators | NEUROGEN CORPORATION (US) | 1994-07-12 | — | — | US | disclosed |
| US-5260292-A | Topical treatment of acne with aminopenicillins | Towsend, Marvin S. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0536360-A4 | TOPICAL TREATMENT OF ACNE | — | 1993-08-04 | — | — | EP | disclosed |
| EP-0536295-A1 | CERTAIN AZACYCLOALKYL IMIDAZOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-04-14 | — | — | EP | disclosed |
| EP-0536360-A1 | TOPICAL TREATMENT OF ACNE | BLOOM, Leonard (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1992015299-A1 | TOPICAL TREATMENT OF ACNE | BLOOM, LEONARD (US) | 1992-09-17 | — | — | WO | disclosed |
| US-5095015-A | G-aminobutyric acid, anticonvulsants, tranquilizers, sleep disorders | NEUROGEN CORPORATION (US) | 1992-03-10 | — | — | US | disclosed |
| WO-1992000296-A1 | CERTAIN AZACYCLOALKYL IMIDAZOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |